SLC25A39 and sarcoma: In the 255 sarcomas of the TCGA PanCancer Atlas Studies, alterations were found for SLC25A39,GLT8D1 and GATAD2A in 0.78%, 1.57%, and 2.75% of cases, respectively24,25.